Avita MedicalRCEL
Recorded

Avita Medical 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration36 minParticipants6

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good day, ladies and gentlemen, and thank you for standing by. Welcome to the AVITA Medical, Inc. Third Quarter 2026 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question at that time, you will need to press star 11 on your telephone keypad. As a reminder, this conference call is being recorded. At this time, I would like to turn the call over to Mr. Ben Atkins, Vice President of Investor Relations.

Ben AtkinsVP of Investor Relations

Sir, please begin. Thank you, operator.

Ben AtkinsVP of Investor Relations

Welcome to AVITA Medical's Third Quarter 2026 Earnings Call. Joining me on today's call are Cary Vance, President and Chief Executive Officer, and David O'Toole, Chief Financial Officer. Today's earnings release and presentation are available on our website at www.avitamedical.com under the Investor Relations section. Before we begin, I would like to remind you that this call includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are neither promises nor guarantees and involve known and unknown risks and uncertainties that could cause actual results to differ materially from any expectations expressed or implied by the forward-looking statements. Please review our most recent filings with the SEC for comprehensive descriptions of the risk factors. Any forward-looking statements provided during this call are based on management's expectations as of today. I will now turn the call over to Kerry.

Cary VancePresident and CEO

Good afternoon in the U.S. and good morning in Australia. As always, we appreciate you making the time to join us on our quarterly update call. Before I discuss the quarter, I want to acknowledge the clinicians caring for patients with serious burn injuries following the devastating fire at the Wainwright Military Base in Alberta, Canada. At their request, we mobilized quickly. We donated about three dozen RECELL units to burn centers in Calgary and Edmonton and sent AVITA staff to train and to support the clinical teams. Within days, the first patient received treatment with RECELL. Serious burn injuries can happen without warning. Responding takes preparation, access to treatment, and people ready to act. I want to thank our team, the clinicians and burn community in Canada, and the American Burn Association for connecting us.

Cary VancePresident and CEO

RECELL is not commercially available in Canada, and we are grateful to Health Canada for acting quickly to facilitate access. This response brings us back to why we do this work, helping people heal from serious wounds and return to their lives. Let me turn to our third quarter performance. Revenue reached $26.1 million, up 53% year-over-year and 20% from the second quarter. RECELL led that growth, supported by increasing adoption of Cohealyx. We will further discuss our product dynamics in a moment. At the same time, we reduced cash use to approximately $600,000 compared with $3.2 million in Q2. We are growing revenue, but we are also managing expenses and cash diligently. That combination continues to improve the financial position of the company. Based on our performance, we are raising full-year revenue guidance for the second consecutive quarter.

Cary VancePresident and CEO

We now expect revenue of $92 million-$94 million for the full year, compared with our previous range of $86 million-$89 million. We also remain on track to achieve cash flow breakeven in the fourth quarter. David will walk through the financial results and our liquidity in more detail. First, I want to put our progress in context. A year ago, our priorities were to stabilize RECELL utilization, rebuild engagement with our core accounts, and improve how we operate. In Q1, we began to see those actions translate into more consistent demand. In Q2, that demand supported further growth and gave us the confidence to raise guidance and establish our cash flow breakeven goal. Q3 builds on that progress. We continue to grow within our accounts. Hospitals are ordering more RECELL, Cohealyx is reaching additional customers, and revenue growth is translating into lower cash use.

Cary VancePresident and CEO

Our commercial approach remains focused. We target high-volume burn and Level I trauma centers where clinicians treat burns, traumatic injuries, and complex surgical wounds. We estimate this focused U.S. addressable market at approximately $1.3 billion annually. Our task is to grow within that market by supporting more physicians, more eligible procedures, and broader use of our portfolio within each account. Let me start with RECELL. U.S. RECELL revenue reached $22.4 million, approximately 20% above Q2. U.S. RECELL volume increased to 3,196 units, up approximately 21% sequentially. That follows an increase of more than 11% in Q2 over Q1. The growth reflects higher procedure volumes and increased ordering across our accounts. RECELL GO and RECELL GO mini give clinicians options for treating different-sized wounds. mini extends the platform into smaller wounds, while RECELL GO supports treatment of larger areas.

Cary VancePresident and CEO

That matters because the opportunity within a hospital extends across different patients, wound sizes, and surgical teams. Our commercial and clinical teams work with physicians to identify appropriate cases, provide training, and support consistent use. As physicians gain experience, they can assess where RECELL fits within their practice. The clinical evidence supporting that work also continues to grow. In October, the Journal of Plastic, Reconstructive & Aesthetic Surgery published a systematic review that examined 99 studies across 13 countries, covering more than two decades of experience with skin cell suspension autografting, essentially RECELL. All six comparative studies that assessed donor skin requirements reported reductions with our technology, while the 18 studies evaluating healing reported either favorable or comparable outcomes. The studies varied in design and quality, but together, they document a broad base of clinical experience across burns and other wound types.

Cary VancePresident and CEO

For clinicians, reducing the amount of donor skin matters. A donor site creates another wound that then needs to heal. Reducing that burden can make a meaningful difference to a patient's recovery. Burn care established RECELL's clinical foundation and remains an important source of growth. We also see opportunity in trauma and surgical repair, where physicians face many of the same challenges in achieving wound closure and healing. As we discussed last quarter, a new category 1 CPT code family for skin cell suspension autografting is scheduled to take effect on January 1, 2027. It will simplify the current structure from eight codes to four, based on wound size and anatomic location. This week, the Centers for Medicare & Medicaid Services, or CMS, issued its final rule and established national relative value units for physicians performing procedures using RECELL under the Medicare Physician Fee Schedule.

Cary VancePresident and CEO

Once effective in January, the new framework will replace today's region-by-region Medicare administrative contractor pricing with nationally published RVUs. Clinicians have shared encouraging feedback about the simpler structure. Our team is ready to support hospitals with coding information and practical implementation guidance. International RECELL revenue was approximately $900,000, essentially flat with Q2. We continue to build experience with RECELL GO in markets where we have regulatory authorization, including the first RECELL GO cases in Australia, where RECELL was originally developed by Dr. Wood. While international remains a smaller contributor today, our focus on training, clinical experience, and local relationships in key markets continues to support steadily broadening adoption over time. Let me turn to Cohealyx. Revenue reached $2.1 million, up approximately 21% from Q2. We continue to add customers as hospitals complete their value analysis committee reviews and begin using Cohealyx.

Cary VancePresident and CEO

Those reviews are an important part of adoption. Hospitals need to assess the clinical evidence, understand the economics, and determine how a product fits into their treatment protocols. The interim Cohealyx I results support those discussions. The study reported a median time to graft readiness of approximately 11 days, with some patients ready within the first week. We expect the complete six-month follow-up data set this month. That will add information on longer-term outcomes to the early evidence we have already shared. Our focus remains on helping hospitals complete their evaluations and supporting clinicians as they gain experience with the product. Turning to PermeaDerm, revenue was approximately $600,000, essentially flat with Q2. At this early stage, the timing of individual orders can affect quarterly comparisons. We are focused on building a broader base of regular use.

Cary VancePresident and CEO

The PermeaDerm I results we reported in August give us stronger evidence to support that work. This randomized study enrolled 40 patients across 11 U.S. burn centers. It compared PermeaDerm with allograft, which is human skin transplanted from a deceased donor, for temporary wound coverage before definitive split-thickness skin grafting. The study met its primary endpoint. PermeaDerm demonstrated a 70% economic advantage over allograft, measured by product cost per percent total body surface area treated. It also reduced preparation time by approximately 96%, with comparable graft take and wound healing outcomes. Approximately 94% of PermeaDerm patients achieved at least 95% graft take one week after autografting. All patients in both groups were healed by eight weeks. These results support a clear role for PermeaDerm as a wound temporizer.

Cary VancePresident and CEO

Hospitals can store it at room temperature and use it without tissue tracking, thawing, and meshing, while maintaining comparable application time in the operating room. Its transparency allows clinicians to assess the wound without removing the covering. Those features address practical challenges in burn care, product availability, preparation time, and visibility of the wound. We have submitted the study for publication and are using the findings in clinical education and hospital evaluations. The commercial work now is to translate that evidence into adoption and repeat use. Across the portfolio, each product serves a distinct purpose. PermeaDerm protects and stabilizes the wound. Cohealyx rebuilds the wound bed. RECELL restores the patient's skin. That gives us several ways to meet clinical needs within the same account based on the patient and the treatment plan.

Cary VancePresident and CEO

The American Burn Association's regional burn conferences provide an important forum for clinicians to share emerging evidence and practical experience. Across the four regional conferences this year, 26 presentations involved AVITA technologies. This surpasses the cumulative presence of several leading competitors. The presentations cover RECELL outcomes in pediatric, geriatric, and other complex burn populations, as well as applications in facial and hand reconstruction and limb salvage. Four include treatment approaches using two or more AVITA products, while others present clinical data for Cohealyx and PermeaDerm. With three regional conferences now completed and one more next week, this high level of engagement highlights the growing adoption of our portfolio and further expands the evidence supporting wider clinical use. Before I hand over to David, I want to put our fourth quarter outlook in the context of the year's progress.

Cary VancePresident and CEO

Our full-year guidance implies Q4 revenue of approximately $24.9 million-$26.9 million. At the midpoint, that would deliver approximately 30% growth for the full year over 2025. Looking across the year, revenue has increased from $19.3 million in Q1 to $21.7 million in Q2, and our Q4 range reflects continued growth from that base. Q3 was particularly strong at $26.1 million and may have benefited a bit from seasonal high burn admissions during the summer. Our guidance accommodates that third quarter variability while reflecting the consistent, stronger sequential performance we have delivered through September. We remain focused on finishing the year strongly and reaching cash flow breakeven. Our priorities are consistent: expand RECELL utilization, grow adoption of Cohealyx and PermeaDerm, and maintain commercial growth and financial discipline. With that, I'll hand it over to David.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day